Length Polymorphism in Heme Oxygenase-1 and Risk of CKD among Patients with Coronary Artery Disease

Yu-Hsin Chen,*† Ko-Lin Kuo,‡ Szu-Chun Hung,‡ Chih-Cheng Hsu,§ Ying-Hwa Chen,*| and Der-Cherng Tarng*¶**††

*Faculty of Medicine, ¶Institute of Clinical Medicine, and **Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan; †Division of Nephrology, Department of Internal Medicine, Taipei City Hospital, Yang-Ming Branch, Taipei, Taiwan; ‡Division of Nephrology, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Taipei, Taiwan; §Division of Geriatrics and Gerontology, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan; and Divisions of Cardiology and Nephrology, Department of Medicine and Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan

ABSTRACT
The length polymorphism of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with cardiovascular events and mortality in high-risk populations. Experimental data suggest that heme oxygenase-1 protects against kidney disease. However, the association between this polymorphism and long-term risk of CKD in high-risk patients is unknown. We analyzed the allelic frequencies of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter in 386 patients with coronary artery disease recruited from January 1999 to July 2001 and followed until August 31, 2012. The S allele represents short repeats (<27), and the L allele represents long repeats (≥27). The primary renal end points consisted of sustained serum creatinine doubling and/or ESRD requiring long-term RRT. The secondary end points were major adverse cardiovascular events and mortality. At the end of study, the adjusted hazard ratios (95% confidence intervals) for each L allele in the additive model were 1.99 (1.27 to 3.14; \( P = 0.003 \)) for the renal end points, 1.70 (1.27 to 2.27; \( P < 0.001 \)) for major adverse cardiovascular events, and 1.36 (1.04 to 1.79; \( P = 0.03 \)) for mortality. With cardiac events as time-dependent covariates, the adjusted hazard ratio for each L allele in the additive model was 1.91 (1.20 to 3.06; \( P = 0.01 \)) for the renal end points. In conclusion, a greater number of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with higher risk for CKD, cardiovascular events, and mortality among patients with coronary artery disease. J Am Soc Nephrol 25: 2669–2677, 2014. doi: 10.1681/ASN.2013111205

Heme oxygenase (HO) is the rate-limiting enzyme in heme degradation. The enzyme generates free iron, biliverdin, and carbon monoxide. Biliverdin is subsequently converted to bilirubin by biliverdin reductase, and free iron is rapidly sequestered by ferritin.\(^1\) HO is a cytoprotective enzyme that potentially exerts antioxidant, anti-inflammatory, and antiapoptotic functions.\(^2\) HO-1 is the inducible isoform, whereas HO-2 is constitutively expressed. HO-1 is expressed in various tissues and is upregulated by cellular stress. HO-1 is known to be protective against atherosclerosis, hepatic ischemia-reperfusion injury, hyperoxia-induced lung injury, and corneal inflammation in experimental studies.\(^3\)–\(^6\)

The human HO-1 gene has been mapped to chromosome 22q12 and the number of guanosine thymidine dinucleotide \([(GT)\_n]\) repeats in the HO-1 gene microsatellite promoter is inversely associated with HO-1 mRNA levels and enzyme activity.\(^7\)–\(^8\)

Received November 19, 2013. Accepted March 16, 2014. Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ying-Hwa Chen, Faculty of Medicine, National Yang-Ming University, and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan, or Dr. Der-Cherng Tarng, Department and Institute of Physiology, National Yang-Ming University, and Division of Nephrology, Department of Medicine and Immunology Center, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan. Email: yhchen@vghtpe.gov.tw or dctarng@vghtpe.gov.tw

Copyright © 2014 by the American Society of Nephrology
Previous studies have demonstrated an increased susceptibility to cardiovascular events and increased mortality of longer \((GT)\_n\) repeats in the HO-1 gene promoter in high-risk populations such as patients with diabetes mellitus, hypercholesterolemia, a history of smoking, peripheral artery disease, or arsenic exposure.\(^8\) Our recent study also showed that longer \((GT)\_n\) repeats in the HO-1 gene promoter were associated with a higher risk of long-term cardiovascular events and mortality in hemodialysis patients.\(^8\) Until now, the investigations for this polymorphism were mostly restricted to graft survival in kidney transplant recipients.\(^8\) The effect of the length polymorphism in the HO-1 gene promoter on the risk of CKD is a largely undefined body of knowledge.

Coronary artery disease (CAD) per se is a major independent risk factor for subsequent development and progression of CKD.\(^19\)–\(^21\) Kiyosue et al. found that the deterioration of renal function was correlated with the severity of CAD in Japanese patients.\(^20\) We recently revealed that the GFR declined faster in CAD than that in normal coronary artery of Taiwanese patients.\(^21\) Longer \((GT)\_n\) repeats in the HO-1 gene promoter associated with long-term outcomes of CAD, such as major adverse cardiovascular events, target vessel revascularization, and overall mortality\(^8\)–\(^12\); however, the relevance of this polymorphism in native kidney function of patients with CAD is unknown. The protective effect of HO-1 against kidney injury is well known in a variety of animal models.\(^2\)–\(^6\),\(^21\),\(^22\)–\(^26\) We therefore performed an association study in patients with CAD to investigate whether the length polymorphism of the HO-1 gene promoter is associated with the risk of CKD.

**RESULTS**

Initially, 402 patients with CAD were enrolled from a tertiary hospital. During a median follow-up period of 10.2 years (interquartile range, 6.31–11.6), 16 patients were excluded from the study because of a follow-up time of <6 months \((n=3)\) and insufficient creatinine follow-up data \((n=13)\). Finally, 386 patients with CAD with a mean age of 70 years were analyzed.

**Length Polymorphism of \((GT)\_n\) Repeats in the HO-1 Gene Promoter**

Figure 1 shows the frequency distribution of \((GT)\_n\) repeats of the HO-1 microsatellite promoter in the 386 patients with CAD and 361 healthy controls. The allelic distribution ranged from 16 to 38 GT repeats, with 23 and 30 GT repeats being the two most common alleles. We chose 27 GT repeats as a cutoff to classify the participants for allele typing, and the cutoff value was consistent with the previously published literature.\(^10\),\(^14\),\(^17\),\(^27\) Thus, short repeats with <27 GT repeats were designated as S alleles, and long repeats with at least 27 GT repeats were designated as L alleles. Accordingly, the participants were categorized into S/S, S/L, or L/L genotypes. In Table 1, the genotype proportions and L-allelic frequencies of HO-1 polymorphism in patients with CAD were comparable with those in healthy controls and Hardy–Weinberg equilibrium was met. In this study, all participants were Taiwanese and had similar ethnic backgrounds. Therefore, statistical artifacts caused by population stratification could be ruled out as described by Pritchard and Rosenberg.\(^28\)

**Baseline Demographic and Laboratory Data**

Patients with CAD among the three genotypes of HO-1 promoter polymorphism had no significant differences in age at entry, sex, comorbidity, LDL and HDL cholesterol levels, and smoking status (Table 2). No significant differences across genotype groups were found in the baseline eGFR, proteinuria, use of statins or renin-angiotensin system blockades, serum albumin, calcium, phosphorus, and hemoglobin levels. Intriguingly, the serum bilirubin level was lower in L allele carriers (L/L and S/L genotypes) and higher in patients with the S/S genotype (Figure 2). Serum ferritin and malondialdehyde levels were highest in the L/L genotype and lower in the S/L and S/S genotypes (Figure 2).

**Figure 1.** Frequency distribution of the number of \((GT)\_n\) repeats of the heme oxygenase-1 microsatellite promoter. There are 386 patients with CAD and 361 healthy controls. The \((GT)\_n\) repeats range from 16 to 38. There is a bimodal distribution with one peak located at 23 repeats and the other located at 30 repeats in both groups. The frequency distributions of \((GT)\_n\) repeats are not significantly different between patients with CAD and healthy controls.

**Table 1.** Genotype and allelic frequency of HO-1 microsatellite promoter polymorphism in healthy controls and patients with CAD

<table>
<thead>
<tr>
<th>Genotype, n (%)</th>
<th>Healthy Controls ((n=361))</th>
<th>Patients with CAD ((n=386))</th>
</tr>
</thead>
<tbody>
<tr>
<td>S/S</td>
<td>78 (21.6)</td>
<td>94 (24.4)</td>
</tr>
<tr>
<td>S/L</td>
<td>194 (53.7)</td>
<td>187 (48.4)</td>
</tr>
<tr>
<td>L/L</td>
<td>89 (24.7)</td>
<td>105 (27.2)</td>
</tr>
<tr>
<td>L-allelic frequency</td>
<td>0.52</td>
<td>0.51</td>
</tr>
<tr>
<td>S allele, number of ((GT)_n) repeats &lt;27; L allelle, number of ((GT)_n) repeats ≥27.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Risk of CKD
At the end of study, 47 patients (12.2%) reached the renal end points, which included sustained serum creatinine doubling and ESRD necessitating long-term RRT. In this study, we used the composite renal end points to evaluate the risk of CKD. To ensure the events were CKD but not AKI, the patients followed-up for fewer than 6 months were ruled out. Data on at least two follow-up creatinine measurements were obtained. The events of creatinine doubling were restricted to sustained high creatinine levels; this means that if the creatinine level regressed to lower than the doubling value during follow-up, the renal end point was not reached. ESRD is defined as necessitating long-term RRT but not for a short temporary period. Moreover, acute elevation of creatinine and dialysis starting before death were assumed to be AKI and were not included in the renal end points. Kaplan–Meier analysis curves among 386 patients with CAD showed that the risk of the renal end points was significantly higher in the L/L genotype than in the S/S genotype (P=0.01) and S allele carriers (S/L and S/S genotypes) (P=0.02) (Figure 3A). When we assessed the association of this polymorphism with each outcome, there were no major differences between the S/S and S/L genotype groups for all three types of cumulative events (Table 3). This implies that a recessive model would best fit the observed data. In the recessive model of a Cox regression analysis, individuals with the L/L genotype had approximately 2.4-fold the risk for the renal end points as the S allele carriers, which led to an adjusted hazard ratio (HR) of 2.43 (95% confidence interval [95% CI], 1.28 to 2.04; P=0.01) (Table 3). In the additive model, each L allele had an adjusted HR of 1.99 (95% CI, 1.27 to 3.14; P=0.003) for the renal end points (Table 3). We further validated that the risk of CKD is independent to the risk of cardiac outcomes that developed during follow-up using the cardiac events as time-dependent covariates in the Cox regression analysis (Table 4). The L/L genotype led to an adjusted HR of 2.41 (95% CI, 1.31 to 4.55; P=0.01) for the renal end points as the S allele carriers, and each L allele had an adjusted HR of 1.91 (95% CI, 1.20 to 3.06; P=0.01) for the renal end points (Table 4).

Major Adverse Cardiovascular Events and All-Cause Mortality
Of the study patients, 101 (26.4%) developed major adverse cardiovascular events and 117 (30.3%) died. Of the deceased

Table 2. Baseline demographic characteristics and laboratory data of patients with CAD stratified by genotypes of HO-1 microsatellite promoter polymorphism

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Patients (n=386)</th>
<th>S/S (n=94)</th>
<th>S/L (n=187)</th>
<th>L/L (n=105)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>70±8</td>
<td>71±8</td>
<td>70±8</td>
<td>71±8</td>
<td>0.76</td>
</tr>
<tr>
<td>Men, %</td>
<td>92.7</td>
<td>93.6</td>
<td>92.5</td>
<td>92.4</td>
<td>0.93</td>
</tr>
<tr>
<td>Current smoker, %</td>
<td>33.1</td>
<td>36.7</td>
<td>30.3</td>
<td>34.7</td>
<td>0.53</td>
</tr>
<tr>
<td>Comorbidities, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>73.8</td>
<td>80.9</td>
<td>73.3</td>
<td>68.6</td>
<td>0.14</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>33.7</td>
<td>30.9</td>
<td>34.8</td>
<td>34.3</td>
<td>0.80</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>12.4</td>
<td>11.7</td>
<td>11.8</td>
<td>14.3</td>
<td>0.80</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>6.5</td>
<td>4.3</td>
<td>5.3</td>
<td>10.5</td>
<td>0.14</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>3.4</td>
<td>5.3</td>
<td>1.1</td>
<td>5.7</td>
<td>0.05</td>
</tr>
<tr>
<td>Total no. of antihypertensive medications, %</td>
<td>2.7±1.6</td>
<td>2.7±1.4</td>
<td>2.5±1.5</td>
<td>3.1±1.7</td>
<td>0.75</td>
</tr>
<tr>
<td>Renin-angiotensin system blockades, %</td>
<td>45.6</td>
<td>45.7</td>
<td>44.9</td>
<td>46.6</td>
<td>0.96</td>
</tr>
<tr>
<td>Statins, %</td>
<td>23.8</td>
<td>24.5</td>
<td>23.5</td>
<td>23.8</td>
<td>0.99</td>
</tr>
<tr>
<td>Laboratory parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine, mg/dl</td>
<td>1.3±0.4</td>
<td>1.3±0.4</td>
<td>1.2±0.3</td>
<td>1.3±0.6</td>
<td>0.22</td>
</tr>
<tr>
<td>eGFR, ml/min per 1.73 m²</td>
<td>64±17</td>
<td>63±17</td>
<td>65±15</td>
<td>63±19</td>
<td>0.44</td>
</tr>
<tr>
<td>Proteinuria, %</td>
<td>12.2</td>
<td>12.1</td>
<td>13.4</td>
<td>10.1</td>
<td>0.71</td>
</tr>
<tr>
<td>Albumin, g/dl</td>
<td>4.1±0.4</td>
<td>4.0±0.4</td>
<td>4.1±0.4</td>
<td>4.1±0.4</td>
<td>0.29</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>187±37</td>
<td>193±41</td>
<td>183±32</td>
<td>188±40</td>
<td>0.08</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>122±27</td>
<td>125±31</td>
<td>121±26</td>
<td>121±27</td>
<td>0.46</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>38±8</td>
<td>38±8</td>
<td>37±8</td>
<td>39±8</td>
<td>0.12</td>
</tr>
<tr>
<td>Triglyceride, mg/dl</td>
<td>151±118</td>
<td>157±103</td>
<td>143±87</td>
<td>159±168</td>
<td>0.46</td>
</tr>
<tr>
<td>Fasting serum glucose, mg/dl</td>
<td>116±46</td>
<td>114±38</td>
<td>115±46</td>
<td>119±51</td>
<td>0.64</td>
</tr>
<tr>
<td>Uric acid, mg/dl</td>
<td>7.3±1.9</td>
<td>7.4±1.7</td>
<td>7.1±2.0</td>
<td>7.3±1.8</td>
<td>0.51</td>
</tr>
<tr>
<td>Calcium, mg/dl</td>
<td>9.0±0.5</td>
<td>9.0±0.6</td>
<td>8.9±0.4</td>
<td>9.0±0.5</td>
<td>0.77</td>
</tr>
<tr>
<td>Phosphorus, mg/dl</td>
<td>3.4±0.6</td>
<td>3.5±0.5</td>
<td>3.4±0.6</td>
<td>3.4±0.7</td>
<td>0.55</td>
</tr>
<tr>
<td>Hemoglobin, g/dl</td>
<td>13.2±1.5</td>
<td>13.3±1.7</td>
<td>13.1±1.5</td>
<td>13.3±1.5</td>
<td>0.43</td>
</tr>
<tr>
<td>Iron, mg/dl</td>
<td>82±98</td>
<td>69±72</td>
<td>83±90</td>
<td>91±129</td>
<td>0.27</td>
</tr>
<tr>
<td>Transferrin saturation, %</td>
<td>26±14</td>
<td>25±13</td>
<td>26±13</td>
<td>28±15</td>
<td>0.26</td>
</tr>
</tbody>
</table>
patients, 42 (35.9%) died from cardiovascular causes. In the Kaplan–Meier curve analyses, the risk of all-cause mortality was significantly higher in the L/L genotype than in the S/S genotype ($P=0.001$) and the S/L genotype ($P=0.01$) (Figure 3B). In the additive model, each L allele had adjusted HRs of 1.70 (95% CI, 1.27 to 2.27; $P<0.001$) for major adverse cardiovascular events and 1.36 (95% CI, 1.04 to 1.79; $P=0.03$) for death, respectively (Table 3).

**DISCUSSION**

This study, with a median follow-up of 10.2 years among 386 patients with CAD, is the first to demonstrate that there is a significantly increased risk of CKD for patients with the L/L genotype in HO-1 gene promoter polymorphism. Individuals with this genotype had approximately 2.4-fold the risk for sustained serum creatinine doubling and/or ESRD necessitating long-term RRT of those with S/S or S/L genotypes. The significant association of this polymorphism with cardiovascular outcome and mortality in patients with CAD also corroborated previous studies in these high-risk populations.8–16 Ample evidence has shown the beneficial effect of HO-1 in experimental kidney disease, including ischemia-reperfusion kidney injury, nephrotoxin or angiotensin II–induced renal injury, kidney transplantation, and diabetic models.2,18,22 Kim et al.23 demonstrated the renoprotective effect of HO-1 using its inducer and inhibitor through an antiapoptotic pathway in the unilateral ureteral obstruction (UUO) model. Kie et al.24 showed that HO-1 deficiency promoted epithelial-mesenchymal transition and renal fibrosis in the UUO model in HO-1 knockout mice. Desbuards et al.25 used hemin, an inducer of HO-1, to attenuate interstitial fibrosis in 5/6 nephrectomized rats via inhibiting TGF-β and caspase-3 expression and increasing bone morphogenetic protein–7 expression. Correa-Costa et al.26 further revealed that pretreatment or delayed treatment with hemin both reduced renal dysfunction and decreased the expression of proinflammatory molecules, fibrosis-related molecules, and collagen deposition in rats subjected to UUO. In addition, HO-2, which contributes the bulk of HO activity in the unstressed kidney, was also suspected to play a protective role in the animal kidney models.29,30 However, the association between the HO-2 gene polymorphism and kidney disease in humans is still obscure.

The mechanism of HO-1 protection in the kidney is related to heme degradation because a large amount of free heme is pro-oxidant, proinflammatory, and proapoptotic and HO-1 is responsible for regulating its cellular levels. HO-1 also exerts protective effects through its reactive products, bilirubin and carbon monoxide.2,18,22 Bilirubin has both antioxidant and anti-inflammatory properties.31,32 In humans, the length of (GT)$_n$ repeats in the HO-1 gene promoter is inversely associated with HO-1 mRNA levels and enzyme activity.8 Because...
HO-1 is a rate-limiting enzyme for bilirubin production, the serum bilirubin concentration is determined in part by this length polymorphism. Our study confirmed previous findings that the L allele was significantly associated with lower serum bilirubin, and the gene explained a large proportion of the variation in bilirubin levels. We further found that patients with the L/L genotype had less ability against oxidative stress and renal function progression may be possible using a Mendelian randomization approach. For example, S alleles result in higher HO-1 expressions of life-long persistence. Therefore, a higher protective effect against renal function decline from these alleles can be expected. The association between the polymorphism with clinical outcomes is less likely to be influenced by reverse causation or confounding.

Human studies assessing the length polymorphism of the HO-1 gene promoter and renal outcome are mostly restricted to graft survival in kidney transplant recipients and the results are conflicting. Only two cross-sectional studies examined the relationship of this polymorphism in CKD. Courtney et al. found that the HO-1 genotype conferred no significant influence on the mean age at commencement of RRT among patients with autosomal dominant polycystic kidney disease or IgA nephropathy. Chin et al. found that the longer length of the HO-1 gene promoter was related to an eGFR < 60 ml/min per 1.73 m² at diagnosis of IgA nephropathy. The discrepancy between our study and that by Courtney et al. may be mainly because the milieu of factors linked to the progression of CKD were not adjusted in the study by Courtney et al. In addition, differences in study populations (autosomal dominant polycystic kidney disease or IgA nephropathy versus CAD), genotype distribution, sample size, and study design (cross-sectional analysis versus longitudinal follow-up) are also noted. To our knowledge, our study is the first longitudinal long-term study to investigate HO-1 promoter polymorphism and risk of CKD.

Given the estimated allele frequency and its effect on serum bilirubin, the L allele of the HO-1 gene promoter is a likely candidate for the reported trait. If approximately 27% of the CAD population has a strong adverse effect in renal function decline because of the HO-1 length polymorphism, it would have significant implications in future CKD prevention for the high-risk population.

Some limitations in this study should be acknowledged. First, this is a single-center study in patients with CAD in the Taiwanese population and confirmatory replication studies in other centers and other populations are needed. Second, the creatinine follow-up interval was not regular in usual clinical care instead of regular study visits, and the creatinine doubling time might be underdiagnosed. Finally, our study was observational in nature, so it cannot prove causality. However, to ensure adequate statistical power (α=0.05; 1−β=0.8; no loss of follow-up), at least 364 patients with CAD should be enrolled to examine a relative risk increment.

Figure 3. Survival curves for renal end points and all-cause mortality by genotypes. Kaplan–Meier cumulative survival curves for renal endpoints (A) and all-cause mortality (B) among the 386 patients with CAD in relation to the genotype of the HO-1 microsatellite promoter polymorphism. The upper panels are the three genotypes (S/S, S/L, and L/L), and the lower panels are the genotypes in a recessive model (S/L+S/S and L/L).
of 40%. Apart from impracticability to conduct a randomized controlled trial, emerging evidence suggests that well designed observational studies could yield comparable outcomes.

In conclusion, this prospective cohort study shows that homozygote L allele carriers exhibited a strong association with higher risk of CKD, major adverse cardiovascular events, and overall mortality among patients with CAD. Further studies are required to validate this association.

**CONCISE METHODS**

**Research Participants**

Study participants were recruited from January 1999 to July 2001 at a tertiary hospital in Taipei, a metropolitan city that is not the arseniasis-endemic area in Taiwan. A total of 419 patients undergoing coronary angiography agreed to participate in this study. Seventeen patients were excluded from the study because of non-CAD (n=4), insignificant CAD (n=11), history of receiving a renal transplant (n=1), and ESRD undergoing dialysis at entry (n=1). CAD was documented by angiographic evidence of at least 75% stenosis of at least one major coronary artery or a history of prior angioplasty, coronary artery bypass surgery, or myocardial infarction by history validated by electrocardiographic changes. During follow-up, patients who had only one or no follow-up creatinine data and who were followed-up for fewer than 6 months were also excluded from the study. A total of 386 patients with CAD were enrolled. A group of 361 healthy controls were also recruited from volunteers who were receiving health checkups. The control patients were enrolled for genotyping of the length polymorphism of (GT)n repeats in the HO-1 gene promoter.

The healthy volunteers had no CAD or cardiovascular or kidney diseases. The study protocol was approved by the institutional review board of Taipei Tzuchi Hospital. Informed consent was obtained from all participants, and our study complies with the Declaration of Helsinki.

**Clinical Data Collection**

Baseline demographic data were recorded at the time of recruitment. Hypertension was defined as a measured systolic BP >140 mmHg, a diastolic BP >90 mmHg, and/or the use of antihypertensive medications. Diabetes was diagnosed on the basis of the World Health Organization criteria. Congestive heart failure was diagnosed as a left ventricular ejection fraction <40% by echocardiography and symptoms/signs of clinical criteria. Cerebrovascular disease was diagnosed as a brain infarction or hemorrhage by brain imaging and clinical symptoms/signs. Peripheral artery disease was diagnosed as an ankle-brachial index ≤0.9 and clinical symptoms/signs.

**Laboratory Measurements**

Venous blood samples were drawn from the patients who had fasted overnight. Albumin was measured using the bromocresol green method. Iron, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, glucose, calcium, phosphorus, and creatinine levels in the serum were determined using commercial kits and a Hitachi 7600
patients with CAD with a median follow-up of 10.2 years

noncardiovascular causes comprising infection, sepsis, malignancy, chemic stroke. All-cause mortality included cardiovascular death and

verse cardiovascular events consist of myocardial infarction and is-

hemodialysis, peritoneal dialysis, or renal transplantation. Major ad-

tients. ESRD means the patients undergo long-term RRT, including

pendently obtained information about the occurrence of interim

to a previously published procedure. The PCR products were mixed

together with the GenoType TAMRA DNA ladder (size range, 50

vanadate oxidation method (Wako Pure Chemical Industries, Ltd.,

Plasma malondialdehyde was determined with a thio-

durine dipstick assay (Clinitek Atlas 10; Bayer HealthCare, Misha-

Autoanalyzer (Roche Modular; Hitachi, Ltd., Tokyo, Japan). The

total iron binding capacity (TIBC) was measured using the TIBC

Microtest (Daiichi, Tokyo, Japan), and serum ferritin was deter-

mined using an RIA (Incstar, Stillwater, MN). Transferrin saturation

calculated as the ratio of serum iron to TIBCand was presented as

percentages. Proteinuria was defined as a value of trace or higher on a

urine dipstick assay (Clinitek Atlas 10; Bayer HealthCare, Mishaw-

ka, IN). Plasma malondialdehyde was determined with a thio-

barbituric acid test. The adducts consisting of two molecules of thio-

barbituric acid were separated by an HPLC method described by

Nielsen et al. Total serum bilirubin was measured using the meta-

vanadate oxidation method (Wako Pure Chemical Industries, Ltd.,

Osaka, Japan).

Length Polymorphism of (GT)_n Repeats in the HO-1 Gene Promoter
Genomic DNAs were extracted from leukocytes with conventional

procedures. The 5’-flanking region containing (GT)_n repeats of the

HO-1 gene was amplified by the PCR with a 5-carboxyfluorescein-

labeled sense primer (5’-AGAGCCTGACGTGTTCTCAGA-3’) and an

antisense primer (5’-ACAAAGTCTGGCCTTGGAC-3’), according to a

previously published procedure. The PCR products were mixed

一起 with the GenoType TAMRA DNA ladder (size range, 50–500

bp; GibcoBRL) and analyzed with an automated DNA sequencer

(ABI Prism 377). Each size of the (GT)_n repeats was calculated

with GeneScan analysis software (PE Applied Biosystems).

Outcome Data Collection
The primary renal end points included sustained serum creatinine

doubling and/or ESRD necessitating long-term RRT from the time of

inclusion in the study. The secondary end points were major adverse

cardiovascular events and all-cause mortality. The cohort was

followed until August 31, 2012. The patients were followed-up for

at least 6 months. A trained physician who was blinded to the length

polymorphism of (GT)_n repeats in the HO-1 gene promoter inde-

pendently obtained information about the occurrence of interim

ESRD, major adverse cardiovascular events, and cause of death by

reviewing hospital records and making phone calls to the study pa-

tients. ESRD means the patients undergo long-term RRT, including

hemodialysis, peritoneal dialysis, or renal transplantation. Major ad-

verse cardiovascular events consist of myocardial infarction and is-

chemic stroke. All-cause mortality included cardiovascular death and

noncardiovascular causes comprising infection, sepsis, malignancy,
gastrointestinal bleeding, chronic obstructive lung disease, and

chronic liver disease.

Statistical Analyses
A comparison of the genotypes and allelic frequencies of the HO-1

microsatellite promoter polymorphism between patients with CAD

and healthy individuals was performed using a chi-squared test. Baseline
descriptive variables were expressed as percentages for categorical data,

means±SDs for continuous data with a normal distribution, and me-

dians (interquartile ranges) for continuous data without a normal dis-

tribution. Potential differences among the three patient groups of the

HO-1 promoter genotype were assessed with ANOVA for normally
distributed data, the Kruskal–Wallis test for non-normally distributed
data, or the Pearson chi-squared test for categorical variables. Cumula-
tive survival curves for the renal end points and all-cause mortality were

generated using the Kaplan–Meier method. Between-group survival

rates among the genotypes of the HO-1 promoter polymorphism were

compared using a log-rank test. The assumption of proportional

hazards was confirmed by a log minus log plot and was met in the Cox

models. A multivariate Cox regression model was used to estimate the

HRs of the renal end points, major adverse cardiovascular events, and

all-cause mortality in relation to the genotypes of the HO-1 microsat-

ellite promoter polymorphism. The analysis was adjusted for age, sex,

smoking status, diabetes, hypertension, prior congestive heart failure,

stroke, and peripheral artery disease, total cholesterol, HDL cholesterol,

serum albumin, hemoglobin, eGFR, presence of proteinuria at baseline,

and use of renin-angiotensin system blockers or statins.

A comparison of the genotypes and allelic frequencies of the

HO-1 microsatellite promoter polymorphism between patients with CAD

and healthy individuals was performed using a chi-squared test. Baseline
descriptive variables were expressed as percentages for categorical data,

means±SDs for continuous data with a normal distribution, and me-

dians (interquartile ranges) for continuous data without a normal dis-

tribution. Potential differences among the three patient groups of the

HO-1 promoter genotype were assessed with ANOVA for normally
distributed data, the Kruskal–Wallis test for non-normally distributed
data, or the Pearson chi-squared test for categorical variables. Cumula-
tive survival curves for the renal end points and all-cause mortality were

generated using the Kaplan–Meier method. Between-group survival

rates among the genotypes of the HO-1 promoter polymorphism were

compared using a log-rank test. The assumption of proportional

hazards was confirmed by a log minus log plot and was met in the Cox

models. A multivariate Cox regression model was used to estimate the

HRs of the renal end points, major adverse cardiovascular events, and

all-cause mortality in relation to the genotypes of the HO-1 microsat-

ellite promoter polymorphism. The analysis was adjusted for age, sex,

smoking status, diabetes, hypertension, prior congestive heart failure,

stroke, and peripheral artery disease, total cholesterol, HDL cholesterol,

serum albumin, hemoglobin, eGFR, presence of proteinuria at baseline,

and use of renin-angiotensin system blockers or statins. Because the

length polymorphism in the HO-1 promoter was significantly associ-

ated with bilirubin, ferritin, and malondialdehyde, these three variables

were not offered simultaneously in a Cox regression model to avoid

multicollinearity. The HRs of the renal end points were further exam-

ined using cardiac events as time-dependent covariates in the Cox re-

gression model in relation to the genotypes of the HO-1 microsat-

ellite promoter polymorphism, total bilirubin, serum ferritin, and malondi-

aldehyde, respectively. Statistical analysis was performed using SPSS soft-

ware (version 16.0; SPSS Inc., Chicago, IL). All P values were two-tailed. P

values<0.05 were considered statistically significant.

ACKNOWLEDGMENTS
We thank P.C. Lee for her expert secretarial assistance and graphic
design.
This study was supported by grants from the National Science Council (NSC 99-2314-B-010-002-MY3 and NSC 102-2314-B-010-004-MY3), the Taipei Veterans General Hospital (V96ER2-012 and V99CI-121), and the Ministry of Education’s Aim for the Top University Plan.

DISCLOSURES

None.

REFERENCES


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2013111205/-/DCSupplemental.